ICAM-1-decorated extracellular vesicles loaded with miR-146a and Glut1 drive immunomodulation and hinder tumor progression in a murine model of breast cancer

Abstract

Tissue nanotransfection (TNT)-driven extracellular vesicles mediate immunomodulation and hinder tumor progression in a mouse model of breast cancer.

Truncated PD1 Engineered Gas‐Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells

“…Notably, tPD1‐PTGFRN in EV tPD1 was much higher than PD1 in EV PD1 , suggesting that there were more tPD1‐PTGFRN displayed per EV, which is consistent with the previous findings that PTGFRN is one of the most abundant proteins found in the EVs. [ 10 ] To explore whether tPD1‐PTGFRN‐engineering changed the size and morphology of the derived EVs, the morphology and size distribution of isolated EVs were characterized by transmission electron microscope and nanoparticle tracking analysis, respectively. Both EV PD1 and EV tPD1 had similar morphology and size as the non‐modified EV None (Figure 1C,D ).…”

“…Duarte‐Sanmiguel et al designed ICAM‐1‐decorated EV loaded with miR‐146a and Glut1, which could drive immunomodulation and hinder tumor progression in a breast cancer model. [ 10 ] Shi et al developed a synthetic multivalent antibodies retargeted exosome (SMART‐Exo) displaying both anti‐human CD3 and anti‐human HER2 antibodies, and the SMART‐Exos dually targeting T cell CD3 and breast cancer‐associated HER2 receptors for immune‐activation. [ 11 ] EVs were also used to pack GSDMD‐N mRNA to induce cell pyroptosis in HER + breast cancer, [ 26 ] in turn the immunogenic pyroptosis induced a robust immunotherapy.…”

“…For example, ICAM-1-decorated EV loaded with miR-146a and Glut1, designed by Duarte-Sanmiguel et al, can drive immunomodulation and hinder tumor progression in a breast cancer model. [10] Similarly, by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, the resultant synthetic multivalent antibodies retargeted exosomes (SMART-Exos), dually target T cell CD3 and breast cancer-associated HER2 receptors and exhibit highly potent and specific anti-tumor activity both in vitro and in vivo. [11] In this study, we proposed to use EVs as vectors to construct a new ultrasound contrast agent, designated as Gp-EV tPD1 .…”

Engineered extracellular vesicle-based gene therapy for the treatment of discogenic back pain

“…Moreover, non-viral systems offer flexibility in the cargo size they can carry while viral vectors have inherent capsid size restriction [ 45 ]. Finally, EVs can be engineered to achieve enhanced tissue tropism and targeting efficiency, which allow them to be delivered locally or systemically to reach specific tissues in the body [ 22 , 25 , 46 ]. Considering the limited vascularity of the IVD, localized injection of eEVs was used as the preferred deployment route over systemic delivery for this study.…”

Tissue Nanotransfection Silicon Chip and Related Electroporation-Based Technologies for In Vivo Tissue Reprogramming

“…Unlike conventional treatments that often affect both healthy and cancerous cells, TNT allows for the delivery of therapeutic genes in a highly localized manner, ensuring maximum impact on the tumor while minimizing side effects. Except for the in vivo gene delivery methods [ 9 , 17 , 19 , 79 ] mentioned in this review, irreversible electroporation is also widely used to induce tumor cell death for cancer treatment [ 81 ].…”